share_log

Wedbush Maintains Outperform on Inozyme Pharma, Announces $15 Price Target

Benzinga ·  Sep 8, 2023 11:00

Wedbush analyst David Nierengarten maintains Inozyme Pharma (NASDAQ:INZY) with a Outperform and announces $15 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment